Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer
Objective To analyze the efficacy and safety of trastuzumab (H) and pertuzumab (P) combined with different chemotherapy regiments in neoadjuvant therapy for HER2-positive breast cancer. Methods We retrospectively analyzed the clinical data of the patients with HER2-positive breast cancer who receive...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2022-01-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0802 |
| _version_ | 1818330338072461312 |
|---|---|
| author | MA Xiangmin ZHANG Xiangmei ZHOU Xinping REN Xiaofei ZHANG Weifang LIU Yunjiang |
| author_facet | MA Xiangmin ZHANG Xiangmei ZHOU Xinping REN Xiaofei ZHANG Weifang LIU Yunjiang |
| author_sort | MA Xiangmin |
| collection | DOAJ |
| description | Objective To analyze the efficacy and safety of trastuzumab (H) and pertuzumab (P) combined with different chemotherapy regiments in neoadjuvant therapy for HER2-positive breast cancer. Methods We retrospectively analyzed the clinical data of the patients with HER2-positive breast cancer who received HP combined with chemotherapy as neoadjuvant therapy and completed surgery. The primary endpoint was total pathologic complete response (tpCR) (ypT0/isypN0), the secondary endpoints were breast pathologic complete response(bpCR) (ypT0/is) and axillary pathologic complete response (apCR) (ypN0), and the factors influencing pCR were analyzed. Results A total of 63 patients were included, of whom 23 were treated with TCbHP, 27 were treated with THP regimen, and 13 were treated with AC-THP. The overall tpCR rate was 65.1%, of which TCbHP was 73.9%, THP was 55.6%, and AC-THP was 69.2%. The tpCR rate of HR-negative patients was 79.2%, higher than that of HR-positive 56.4%. The overall bpCR rate was 69.8%, and apCR rate was 81.0%. Univariate analysis showed that HER2 status was a related factor affecting tpCR (P=0.023). The total effective rate by MRI was 87.3%. The level 3 and 4 toxicity of the TCbHP regimen was slightly higher than those of the THP and the AC-THP regimens. Conclusion HP combined with chemotherapy have achieved relatively high pCR. HER2 status is a related factor that affects tpCR. The adverse reactions are controllable. |
| first_indexed | 2024-12-13T13:02:22Z |
| format | Article |
| id | doaj.art-dd1ebe3cc7f846d290434af3a23ae285 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-12-13T13:02:22Z |
| publishDate | 2022-01-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-dd1ebe3cc7f846d290434af3a23ae2852022-12-21T23:44:58ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782022-01-01491465210.3971/j.issn.1000-8578.2022.21.08028578.2022.21.0802Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast CancerMA Xiangmin0ZHANG Xiangmei1ZHOU Xinping2REN Xiaofei3ZHANG Weifang4LIU Yunjiang5Department of Breast Surgery, Handan Central Hospital, Handan 056001, ChinaResearch Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, ChinaDepartment of Breast Surgery, Handan Central Hospital, Handan 056001, ChinaBreast Center, Fourth Hospital of Hebei Medical University Shijiazhuang 050011, ChinaBreast Center, Fourth Hospital of Hebei Medical University Shijiazhuang 050011, ChinaBreast Center, Fourth Hospital of Hebei Medical University Shijiazhuang 050011, ChinaObjective To analyze the efficacy and safety of trastuzumab (H) and pertuzumab (P) combined with different chemotherapy regiments in neoadjuvant therapy for HER2-positive breast cancer. Methods We retrospectively analyzed the clinical data of the patients with HER2-positive breast cancer who received HP combined with chemotherapy as neoadjuvant therapy and completed surgery. The primary endpoint was total pathologic complete response (tpCR) (ypT0/isypN0), the secondary endpoints were breast pathologic complete response(bpCR) (ypT0/is) and axillary pathologic complete response (apCR) (ypN0), and the factors influencing pCR were analyzed. Results A total of 63 patients were included, of whom 23 were treated with TCbHP, 27 were treated with THP regimen, and 13 were treated with AC-THP. The overall tpCR rate was 65.1%, of which TCbHP was 73.9%, THP was 55.6%, and AC-THP was 69.2%. The tpCR rate of HR-negative patients was 79.2%, higher than that of HR-positive 56.4%. The overall bpCR rate was 69.8%, and apCR rate was 81.0%. Univariate analysis showed that HER2 status was a related factor affecting tpCR (P=0.023). The total effective rate by MRI was 87.3%. The level 3 and 4 toxicity of the TCbHP regimen was slightly higher than those of the THP and the AC-THP regimens. Conclusion HP combined with chemotherapy have achieved relatively high pCR. HER2 status is a related factor that affects tpCR. The adverse reactions are controllable.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0802breast cancerher2neoadjuvant therapytrastuzumabpertuzumabpathological complete response |
| spellingShingle | MA Xiangmin ZHANG Xiangmei ZHOU Xinping REN Xiaofei ZHANG Weifang LIU Yunjiang Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer Zhongliu Fangzhi Yanjiu breast cancer her2 neoadjuvant therapy trastuzumab pertuzumab pathological complete response |
| title | Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer |
| title_full | Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer |
| title_fullStr | Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer |
| title_full_unstemmed | Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer |
| title_short | Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer |
| title_sort | real world research of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment of her2 positive breast cancer |
| topic | breast cancer her2 neoadjuvant therapy trastuzumab pertuzumab pathological complete response |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0802 |
| work_keys_str_mv | AT maxiangmin realworldresearchoftrastuzumabandpertuzumabcombinedwithchemotherapyinneoadjuvanttreatmentofher2positivebreastcancer AT zhangxiangmei realworldresearchoftrastuzumabandpertuzumabcombinedwithchemotherapyinneoadjuvanttreatmentofher2positivebreastcancer AT zhouxinping realworldresearchoftrastuzumabandpertuzumabcombinedwithchemotherapyinneoadjuvanttreatmentofher2positivebreastcancer AT renxiaofei realworldresearchoftrastuzumabandpertuzumabcombinedwithchemotherapyinneoadjuvanttreatmentofher2positivebreastcancer AT zhangweifang realworldresearchoftrastuzumabandpertuzumabcombinedwithchemotherapyinneoadjuvanttreatmentofher2positivebreastcancer AT liuyunjiang realworldresearchoftrastuzumabandpertuzumabcombinedwithchemotherapyinneoadjuvanttreatmentofher2positivebreastcancer |